These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16198027)

  • 1. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.
    Halperin SA; Dobson S; McNeil S; Langley JM; Smith B; McCall-Sani R; Levitt D; Nest GV; Gennevois D; Eiden JJ
    Vaccine; 2006 Jan; 24(1):20-6. PubMed ID: 16198027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
    Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
    Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults.
    Halperin SA; McNeil S; Langley JM; Smith B; MacKinnon-Cameron D; McCall-Sani R; Heyward WL; Martin JT
    Vaccine; 2012 Aug; 30(36):5445-8. PubMed ID: 22704926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
    Raz R; Koren R; Bass D
    Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
    Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
    Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
    Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine.
    Shafran SD; Mashinter LD; Lindemulder A; Taylor GD; Chiu I
    HIV Med; 2007 Jul; 8(5):295-9. PubMed ID: 17561875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of HBV vaccine during stated shelf-life.
    Gloriani NG; Srinivasa K; Bock HL; Hoet B
    Southeast Asian J Trop Med Public Health; 2010 Jul; 41(4):876-82. PubMed ID: 21073062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
    Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
    Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
    Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders.
    Lin C; Zhu J; Zheng Y; Chen Y; Wu Z; Chong Y; Gao Z
    J Infect; 2010 Apr; 60(4):264-70. PubMed ID: 20138189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.
    Halperin SA; Van Nest G; Smith B; Abtahi S; Whiley H; Eiden JJ
    Vaccine; 2003 Jun; 21(19-20):2461-7. PubMed ID: 12744879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
    Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
    J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.
    Schiff GM; Sherwood JR; Zeldis JB; Krause DS
    J Adolesc Health; 1995 Jan; 16(1):12-7. PubMed ID: 7742331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine.
    Halperin SA; Ward BJ; Dionne M; Langley JM; McNeil SA; Smith B; Mackinnon-Cameron D; Heyward WL; Martin JT
    Hum Vaccin Immunother; 2013 Jul; 9(7):1438-44. PubMed ID: 23571179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines.
    Zuckerman JN; Zuckerman AJ; Symington I; Du W; Williams A; Dickson B; Young MD;
    Hepatology; 2001 Oct; 34(4 Pt 1):798-802. PubMed ID: 11584378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
    Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
    J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of two different vaccination schemes against Hepatitis A and B in Mexican children and adolescents].
    González-Huezo MS; Sánchez-Avila F; García Mayol M; Castro Narro G; Sixtos S; Lisker-Melman M; Kershenobich D
    Rev Gastroenterol Mex; 2003; 68(4):271-6. PubMed ID: 15125329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
    Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
    Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.